Shilpa Medicare Limited — Important, 23-01-2025: General Updates

Shilpa Pharma Lifesciences Limited, a 100% subsidiary of Shilpa Medicare Limited, has secured a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Healthcare for its active pharmaceutical ingredient (API), Teriflunomide. This API is a novel disease-modifying agent for the treatment of multiple sclerosis (MS), proven effective in several large phase III clinical trials. Its oral administration offers a significant advantage for patients. The receipt of the 25th CEP underscores Shilpa's dedication to producing high-quality products that meet international standards, enhancing its position in the growing market for MS therapies. Investors should view this development positively, as it not only signifies regulatory validation but also expands Shilpa's product portfolio, potentially leading to increased market share and revenue growth.